A Zantac lawsuit is a legal claim for financial compensation by plaintiffs who took the heartburn medication and were then diagnosed with cancer. Zantac (and the generic version ranitidine) has been found to contain the carcinogen NDMA. Studies have linked NDMA to cancer in animals and humans. In the current litigation, plaintiffs allege Zantac makers placed on the market a dangerous product and failed to warn consumers of the serious risks and side effects.
On April 1, 2020, the Food and Drug Administration (FDA) requested that all companies withdraw their ranitidine products. The FDA had found “unacceptable amounts” of NDMA in the ingredient ranitidine. Since then, more than a dozen pharmaceutical companies have recalled the drug.
Shouse Law Group is a law firm that helps Zantac victims throughout the United States. We represent victims who took both the prescription, over-the-counter and generic ranitidine versions. We are fighting to collect money damages to cover doctor’s bills, lost earnings, and pain and suffering.
Our ranitidine lawsuits are not part of a class action. Instead, they are individual lawsuits of the victim against the drugmaker. Many of the claims will join into a Zantac multidistrict litigation (MDL). This will expedite the settlement process.
We are accepting clients who took Zantac / ranitidine and who then developed one of the following cancers:
- Bladder cancer
- Brain cancer
- Breast cancer
- Colorectal cancer
- Esophageal cancer
- Intestinal cancer
- Kidney (renal) cancer,
- Leukemia (acute lymphoblastic)
- Liver cancer
- Lung cancer
- Multiple myeloma
- Non-hodgkin lymphoma
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Stomach cancer
- Testicular cancer
- Throat and nasal cancer
- Thyroid cancer
- Uterine cancer
There is a short statute of limitations to file suit. So be sure to consult with an attorney quickly.
In this article, our Zantac lawyers discuss:
- 1. What are the grounds for a Zantac lawsuit?
- 2. What is the evidence that Zantac cause cancer?
- 3. Is this a class action or individual lawsuits?
- 4. Has Zantac been recalled?
- 5. Have Zantac lawyers made any settlements yet?
- 6. Who makes Zantac?
- 7. What are Zantac’s long-term effects?
- 8. What are recent Zantac cases?
Two claims victims can sue drug manufacturers for are:
- The drug had a defective design, and
- The drug’s labeling failed to warn about its risks
1.1 Defective design
Courts hold ranitidine manufacturers to a strict liability standard. Therefore, drug makers are responsible if:
- The drug’s defective design posed a foreseeable risk, and
- The drug was manufactured and used as it was supposed to be1
According to online pharmacy Valisure, ranitidine molecules are inherently unstable. When a person ingests a normal dosage, the active ingredient ranitidine hydrochloride converts into the carcinogen NDMA (N-nitrosodimethylamine). In short, NDMA is a natural by-product of ranitidine’s ingredients.2
Therefore, it does not matter which pharmaceutical company manufactured the drug. By design, Zantac reacts with the body’s chemistry to create NDMA. Therefore, all lots of Zantac are potentially cancer-causing.
Common evidence of design defects includes the original Zantac formula. Plaintiffs’ attorneys will also rely on expert witnesses to testify about the design problems.
1.2 Improper labeling and failure to warn
Like all medications, Zantac has a warning label. But its label omits any mention of its carcinogenic risks.
Had physicians been informed of the risks, they may not have recommended or prescribed Zantac. And had patients known of the risks, they may have elected against taking it.
The best evidence of failure to warn is the Zantac packaging itself. Its omission of NDMA-related information suggests consumers were not fully informed of the dangers.
(In some states, brand name drug manufacturers have a legal duty to warn users of generic versions they do not make. In other states, these manufacturers do not have a duty to warn. So which state the victim sues in will dictate how to craft the lawsuit.)3
According to online pharmacy Valisure, ranitidine’s inherent instability causes a chemical reaction that produces high levels of NDMA in the digestive tract. This is particularly true when nitrates are present.
The FDA disagrees. It claims that typical stomach conditions should not cause ranitidine to metabolize into NDMA. Instead, the FDA maintains that NDMA is an impurity found in the drug itself. But on April 1, 2020, it also admitted that storing ranitidine at higher than room temperature “may result in consumer exposure to unacceptable levels of this impurity.”4
Either way, the World Health Organization and the US Environmental Protection Agency (EPA) classify NDMA as a “probable human carcinogen.” In other words, it probably causes cancer in people. Currently, research scientists use NDMA to induce cancer in lab rats for research purposes.5 NDMA has actually been used to make rocket fuel. It has also been found in the blood pressure medicines Valsartan and Losartan. These drugs are also the subject of a large set of lawsuits by cancer victims.
NDMA exposure is safe in humans if limited to 96 nanograms per day.6 But one tablet of the heartburn drug Zantac contains about 2.5 to 3 million nanograms. That is 26,000 to 31,000 times the recommended daily maximum.7 And studies show that people who take Zantac have a 400-fold increase of NDMA levels in their urine.8 It will be difficult for drug companies to deny the increased cancer risk that this level of exposure causes.
Plaintiffs in a Zantac lawsuit need proof they took the drug. Frequent usage over a sustained period of time strengthens their case. Helpful evidence includes:
- Pharmacy records (if the Zantac was prescribed),
- Prescription records from a health care provider,
- Pill bottles/ packaging, and
- Medical records that show the plaintiff developed cancer after taking Zantac
It may be challenging for OTC (over the counter) users to show proof of Zantac usage. Most people do not keep their receipts or pill bottles. But the following records could help:
- Rx prescription drug cards,
- Health flexible spending accounts (FSA),
- Health saving accounts (HSA),
- Health reimbursement accounts (HRA), and/or
- Affidavits or declarations by the victim that he/she took OTC Zantac
Individual rather than class-action lawsuits. But every Zantac lawsuit will eventually be joined into an MDL -- short for “multi-district litigation.” MDLs are a way for courts to streamline pretrial proceedings. Eventually, the MDL judge will permit a handful of cases to proceed to trial. The results of these bellwether trials set the tone for future negotiations.
MDLs are fundamentally different from class actions. In MDLs, every case remains separate. In class actions, they are all combined.
On April 1, 2020, the FDA issued in effect a Zantac recall requesting that all name-brand and ranitidine manufacturers withdraw the drug. This follows a warning the FDA issued on September 13, 2019. In the interim, more than a dozen manufacturers have made a voluntary recall of their ranitidine products:
|Recall Date||Brand Name||Recalled Product||Company|
|02/27/2020||American Health Packaging||Ranitidine Tablets, USP 150mg||American Health Packaging|
|01/08/2020||Mylan Pharmaceuticals Inc.||Nizatidine Capsules 150mg and 300mg (similar to Ranitidine)||Mylan N.V.|
|01/08/2020||Northwind||Ranitidine Tablets 150mg and 300mg||Denton Pharma, Inc. dba Northwind Pharmaceuticals|
|01/07/2020||ani||Ranitidine Tablets 150mg and 300mg||Appco Pharma LLC|
|12/17/2019||Glenmark||Ranitidine Tablets 150mg and 300mg||Glenmark Pharmaceuticals, Inc.|
|11/22/2019||Amneal||Ranitidine Tablets, 150 mg and 300 mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL||Amneal Pharmaceuticals, LLC|
|11/19/2019||PrecisionDose||Ranitidine Oral Solution, USP 150 mg/10 mL||Precision Dose Inc.|
|11/15/2019||GSMS Incorporated||Ranitidine HCl 150mg and 300mg Capsules||GSMS, Inc.|
|11/08/2019||AHP||Ranitidine Liquid Unit Dose Cups||American Health Packaging|
|11/06/2019||Aurobindo & DG Health||Ranitidine||Aurobindo Pharma USA, Inc.|
|10/25/2019||Novitium Pharma||Ranitidine Hydrochloride Capsules 150 mg and 300 mg||Novitium Pharma|
|10/25/2019||Lannett Company, Inc.||Ranitidine Syrup (Ranitidine Oral Solution, USP), 15mg/mL||Lannett Company, Inc.|
|10/23/2019||Dr. Reddy’s, Kroger, Walgreens, and others||Ranitidine Tablets & Capsules||Dr. Reddy’s Laboratories Ltd.|
|10/23/2019||Sanofi||Zantac 150, Zantac 150 Cool Mint, Zantac 75 (OTC Products)||Sanofi|
|10/23/2019||Perrigo Company plc||Ranitidine (all pack sizes)||Perrigo Company plc|
|09/25/2019||Apotex Corp.||Ranitidine Tablets 75mg and 150mg||Apotex Corp.|
|09/23/2019||Sandoz Inc.||Ranitidine Hydrochloride Capsules||Sandoz Inc.|
The FDA also asked manufacturers to do their own laboratory tests on all their ranitidine products and to mail the FDA samples. The FDA further instructed manufacturers not to sell any lots that show more than the daily NDMA limit of 96 nanograms. And manufacturers must notify the FDA if any lots do exceed the NDMA limit.
The following are some of the retailers that stopped selling ranitidine:
- Walgreens, and
- Rite Aid
Alternatives to Zantac that do not contain NDMA include:
- Pepcid (famotidine),
- Tagamet (cimetidine),
- Nexium (esomeprazole),
- Prevacid (lansoprazole), and
- Prilosec (omeprazole)
No. Settlement talks typically do not begin until some cases go to trial. How these bellwether trials turn out helps gauge what money victims can demand. Predictably, plaintiffs attorneys are aiming very high. No amount of millions can make up for getting cancer.
MDL settlements typically resolve through either:
- Global (or matrix) settlements: Defendants pay out a sum that covers all claims. And plaintiffs’ attorneys use a matrix of criteria to determine how much each plaintiff receives; or
- Inventory settlements: Each plaintiff agrees to an acceptable minimum amount. And if their attorneys win a larger amount, each client will receive a percentage of the bonus funds.
More than 10 manufacturers make prescription Zantac. And more than 20 make OTC Zantac. Manufacturers that have recalled its ranitidine products include:
- American Health Packaging
- Amneal Pharmaceuticals, LLC
- Apotex Corp.
- Appco Pharma LLC
- Aurobindo Pharma USA
- Denton Pharma, Inc. dba Northwind Pharmaceuticals
- Dr. Reddy’s Laboratories Ltd.
- Glenmark Pharmaceutical Inc.
- GSMS, Inc.
- Lannett Company, Inc.
- Novitium Pharma
- Perrigo Company plc
- Precision Dose Inc.
- Sandoz Inc.
GSK originally developed prescription ranitidine in 1977. It was FDA-approved in 1983 and went generic the following year. As an H2 blocker antacid, ranitidine drugs help to neutralize stomach acid and prevent and treat:
- GERD (gastroesophageal reflux disease),
- Acid reflux, and
- Sour stomach
Ranitidine is available in various forms, including capsules, tablets, and syrup. Common dosages include 75 mg, 150 mg, and 300 mg.
Ranitidine was one of the first drugs to bring in a billion dollars in sales.9
Cancer is not the only potential consequence of taking Zantac. Twenty conditions ranitidine users may also experience include:
- Liver failure or reduced liver function
- Reduced kidney function
- Reduced lung function
- Enlarged liver
- Skin rash
- Hair loss
- Vitamin B-12 deficiency
- Reduced platelet levels
- Cardiac arrhythmia (irregular heartbeat) and/or tachycardia (rapid heartbeat)
- Nervous system problems
- Elevated pneumonia risks
- Nausea and vomiting
- Stomach cramps, constipation and/or diarrhea
- Dizziness, drowsiness, and/or sleep problems
- Tender breasts (in males)
- Decreased sex drive
Currently, there is an MDL out of the Southern District of Florida (West Palm Beach). The MDL number is 2924. The judge is US District Judge Robin L. Rosenberg. The defendants include:
- Boehringer Ingelheim Pharmaceuticals, Inc.;
- GlaxoSmithKline LLC; Pfizer Inc.;
- Sanofi-Aventis U.S. LLC;
- Sanofi US Services Inc.; and
- Chattem, Inc.
This MDL is for people who developed cancer after taking ranitidine. All similar lawsuits will be consolidated into this MDL. And they are seeking substantial damages to cover all of their expenses.
There currently are some pending class actions against ranitidine manufacturers. But they are geared for people who bought ranitidine but have not gotten sick:
The first class action was filed on Sept. 13, 2019 in the Northern District of California federal court. The plaintiffs claim Sanofi and Boehringer Ingelheim knowingly made and sold OTC Zantac with a carcinogen. These plaintiffs want their money back. They would not have bought the ranitidine had they known of the risks.
Another class action with 13 plaintiffs was filed in the Southern District of Ohio federal court on January 22, 2020. Plaintiffs are seeking equitable remedies. This includes medical monitoring.10
If you or a family member were diagnosed with cancer after taking Zantac, call or attorneys for a free case evaluation. Or fill out the form on this page. We offer free consultations 24/7.
- Valisure, Citizen Petition on Ranitidine (September 9, 2019).
- See, e.g., Mut. Pharm. Co. v. Bartlett, 570 U.S. 472, 481-483 (2013); see, e.g., TH Novartis Pharm Corp., 4 Cal 5th 145, 407 P.3d 18 (Cal. 2017); Katie Thomas, “In 5-4 Ruling, Justices Say Generic Makers Are Not Liable for Design of Drugs“, New York Times (June 24, 2013).
- 12/4/2019: UPDATE – FDA requires additional testing of ranitidine and nizatidine as part of agency’s ongoing effort to help ensure product safety for patients and consumers, FDA Updates and Press Announcements on NDMA in Zantac (ranitidine); 4/1/20: FDA Requests Removal of All Ranitidine Products (Zantac) from the Market.
- Technical Fact Sheet – N-Nitroso-dimethylamine (NDMA), EPA (January 2014).
- See note 4.
- See note 2.
- Teng Zeng, William A. Mitch, Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine, Carcinogenesis, Volume 37, Issue 6, June 2016, Pages 625–634.
- TIMELINE-Popular heartburn medicine Zantac pulled off store shelves, CNBC.com (October 2, 2019).
- MDL transfer order; Garza et al v. Sanofi-Aventis U.S. LLC et al, 19-cv-05772, U.S. District Court for the Northern District of California (filed September 13, 2019); Dodson et. al. v. Sanofi et. al, Case No. 20-356, U.S. District Court for the Southern District of Ohio (filed January 22, 2020).